Eli Lilly and Company(LLY)
INDIANAPOLIS, IN
Pharmaceutical2 H-1B visas (FY2023)Focus: Biologics Discovery
Error: Unreachable/Blocked
DiabetesOncologyNeuroscienceImmunology
Funding Stage
PUBLIC
Employees
43,000
Open Jobs
856
Products & Portfolio (14)
36 discontinued products not shown
ADCIRCA
tadalafil
LOE Approaching
ORAL · TABLET
Phosphodiesterase 5 Inhibitors
pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise abilityhypertension
2009
30
ALIMTA
pemetrexed
LOE Approaching
INJECTION · INJECTABLE
folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.
non-small cell lung cancerlung cancer
2004
30
ALIMTA
pemetrexed disodium
LOE Approaching
INTRAVENOUS · POWDER
folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.
non-small cell lung cancerlung cancer
2004
30
BASAGLAR
insulin glargine
Peak
SUBCUTANEOUS · SOLUTION
insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
glycemic control in adultstype 2 diabetes mellitustype 1 diabetes mellitus
2015
30
CIALIS
tadalafil
LOE Approaching
ORAL · TABLET
Phosphodiesterase 5 Inhibitors
erectile dysfunction (ED)the signssymptoms of benign prostatic hyperplasia (BPH)+1 more
2003
30
CYMBALTA
duloxetine hydrochloride
LOE Approaching
ORAL · CAPSULE, DELAYED REL PELLETS
antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.
the following conditions: Major depressive disorder (MDD) in adults () Generalized anxiety disorder (GAD) in adultsolder () Diabetic peripheral neuropathic pain (DPNP) in adults () Fibromyalgia (FM) in adultsolder () Chronic musculoskeletal pain in adults ()+1 more
2008
30
CYMBALTA
duloxetine hydrochloride
LOE Approaching
ORAL · CAPSULE, DELAYED REL PELLETS
antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.
the following conditions: Major depressive disorder (MDD) in adults () Generalized anxiety disorder (GAD) in adultsolder () Diabetic peripheral neuropathic pain (DPNP) in adults () Fibromyalgia (FM) in adultsolder () Chronic musculoskeletal pain in adults ()+1 more
2004
30
CYMBALTA
duloxetine hydrochloride
LOE Approaching
ORAL · CAPSULE, DELAYED REL PELLETS
antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.
the following conditions: Major depressive disorder (MDD) in adults () Generalized anxiety disorder (GAD) in adultsolder () Diabetic peripheral neuropathic pain (DPNP) in adults () Fibromyalgia (FM) in adultsolder () Chronic musculoskeletal pain in adults ()+1 more
2010
30
CYRAMZA
ramucirumab
Peak
mAbINJECTION · INJECTABLE
VEGFR2 Inhibitors
metastaticgastricgastro-esophageal junction (GEJ) adenocarcinoma with disease progression on+11 more
2014
30
EBGLYSS
lebrikizumab-lbkz
Growth
mAbINJECTION · INJECTABLE
Interleukin-13 Antagonists
olderthose therapies are not advisableatopic dermatitis
2024
30
EMGALITY
galcanezumab-gnlm
Peak
mAbINJECTION · INJECTABLE
Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
episodic cluster headache in adultsmigraine
2018
30
EVISTA
raloxifene hydrochloride
LOE Approaching
ORAL · TABLET
agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism). The agonistic or antagonistic action of raloxifene depends on the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promoters. Raloxifene appears to act as an estrogen agonist in bone. It decreases bone resorption and bone turnover, increases bone mineral density (BMD) and decreases fracture incidence. Preclinical data demonstrate that raloxifene is an estrogen antagonist in uterine and breast tissues. These results are consistent with findings in clinical trials, which suggest that EVISTA lacks estrogen-like effects on the uterus and breast tissue.
invasive breast cancerreduction of the risk of recurrence of breast cancerreduction of risk of noninvasive breast cancer+3 more
2007
30
Pipeline & Clinical Trials
Glucagon receptor antagonist LY2409021
Diabetes After Total PancreatectomyClinical Trials (1)
NCT02944110Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism
N/ALY2503029
CancerClinical Trials (1)
NCT02632994Master Rollover Protocol for Continued Safety Assessment of Study Drug
N/ASelpercatinib
Non Small Cell Lung CancerClinical Trials (5)
NCT05668962Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Phase 2NCT04280081A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Phase 2NCT06458036Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Phase 2+2 more
Treatment for Fibromyalgia
FibromyalgiaClinical Trials (1)
NCT00725101Fibromyalgia Health Outcome Study on Cost of Treatments
N/AThere are no interventions in this study. All participants complete online surveys.
Lung Cancer PatientsPropranolol
HealthyClinical Trials (1)
NCT04682184A Study of Continuous Heart Rate Monitoring in Healthy Participants
N/AAM0010
MelanomaClinical Trials (1)
NCT03554434An Expanded Access Program for AM0010 (Pegilodecakin)
N/AMirikizumab Real World Protocol
Ulcerative ColitisClinical Trials (1)
NCT06696014Mirikizumab Real World Protocol
N/AObservational Study of Pergolide Mesylate and Cardiac Valvulopathy
Parkinson DiseaseClinical Trials (1)
NCT00311532Observational Study of Pergolide Mesylate and Cardiac Valvulopathy
N/AFluoxetine
Major Depressive DisorderClinical Trials (1)
NCT00208897Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?
N/AAID System
Type 1 Diabetes MellitusClinical Trials (1)
NCT03743285A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)
N/AForteo
OsteoporosisClinical Trials (1)
NCT01155245Teriparatide (PTH) and Bone Strength in Postmenopausal Women
N/ANatural History Study
Sensorineural Hearing Loss, BilateralClinical Trials (2)
NCT05572073Otoferlin Gene-mediated Hearing Loss Natural History Study
N/ANCT03997981Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
N/AOlaratumab
Soft Tissue SarcomaClinical Trials (1)
NCT03994627Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
N/ARetinal scan
Cognitive DysfunctionClinical Trials (1)
NCT07254234A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's Disease
N/Aantipsychotic dose increase
SchizophreniaClinical Trials (1)
NCT00712660Study With Information Technology (IT) - Aided Preventive Program in Schizophrenia
N/ADuloxetine Hydrochloride
Major Depressive DisorderClinical Trials (1)
NCT00071708Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
N/Apatient magazine
OsteoporosisClinical Trials (1)
NCT01109472Improving Osteoporosis Care in a Home Health Setting
N/AClinical Trials (1)
NCT01077323A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents
N/ACelecoxib
HealthyClinical Trials (1)
NCT02413203Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B
N/ATherapy for head and neck cancer
Head and Neck CancerClinical Trials (1)
NCT01080313Head and Neck Cancer Registry (LORHAN)
N/AEvolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
Metastatic Breast Canceratomoxetine
Cerebrovascular AccidentClinical Trials (1)
NCT00634439Safety Study of Atomoxetine and Cerebrovascular Outcomes
N/ATeriparatide
Osteoporosis, PostmenopausalClinical Trials (1)
NCT00696644A Study for Teriparatide in Severe Osteoporosis
N/AFlutemetamol F18 Injection
Alzheimer DiseaserTMS Treatment
DepressionClinical Trials (1)
NCT00587639An Evaluation of Safety and Feasibility Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression
N/AActive Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linag
Diabetes Mellitus, Type 2Insulins
Diabetes Mellitus, Type 2Clinical Trials (1)
NCT01055808Observational Study in Japanese Type 2 Diabetes Patients
N/At:slim X2 insulin pump with Control-IQ technology 1.5
Type 1 DiabetesClinical Trials (1)
NCT05403502Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
N/ACharacterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Ma
Type 2 DiabetesVentriculo-peritonal shunting
Normal Pressure HydrocephalusClinical Trials (1)
NCT00149721Anterior Pituitary Function in Patients With Hydrocephalus
N/AHarvard Apparatus syringe pump
HealthyClinical Trials (1)
NCT06516913A Study of Subcutaneous Injection in Healthy Participants
N/ACBT Based Self-help Workbook + Counseling Telepho
Attention-Deficit/Hyperactivity DisorderClinical Trials (1)
NCT01660464Guided Self-Help for Parents of Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
N/AImplementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD
Chronic Kidney Disease(CKD)White Matter in Pediatric Bipolar Disorder: A DTI Study
Bipolar DisorderMetastasis biopsy
Breast CancerClinical Trials (1)
NCT03958136Clinico-biological Data Collection Study of Metastatic Breast Cancer
N/AAn Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Ty
Diabetes Mellitus, Type 2Clinical Trials (1)
NCT01400971An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
N/ABioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients wit
Atopic DermatitisDRMS
DiabetesClinical Trials (1)
NCT01354015Diabetes Remote Care Management System
N/AMolecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: In
Systemic Autoimmune DiseasesClinical Trials (1)
NCT02890134Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort
N/ACLassification of Axial SpondyloarthritiS Inception Cohort
SpondyloarthritisNew Daily Persistent Headache Biomarkers Study
New Daily Persistent HeadacheClinical Trials (1)
NCT04260087New Daily Persistent Headache Biomarkers Study
N/AInterview
CaregiverMetastatic Breast Cancer in Austria
Breast CancerIntense Education Intervention
Diabetes Mellitus, Type 2MiniMed 780G System
Type 1 DiabetesClinical Trials (1)
NCT05325294Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®
N/AMil Familias-Santa Barbara's Operational Pilot to Understand Diabetes in the Latino Community
Type2 Diabetes MellitusClinical Trials (1)
NCT03736486Mil Familias-Santa Barbara's Operational Pilot to Understand Diabetes in the Latino Community
N/Alimited lymphadenectomy
Bladder CancerClinical Trials (1)
NCT01215071Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA
N/ADiabetes Self-Management Education
DiabetesMeal-Tagging App and Web-based Portal:
Type 1 DiabetesClinical Trials (1)
NCT04667182A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes
N/AOpen Jobs (856)
Advisor - Scientific Machine Learning Scientist - Drug Delivery Device Development
US, Indianapolis IN
Data Science & AI2d ago
$126K - $205K/yr
Associate/Director – Joint Process Team
India, Hyderabad
Research & Development2d ago
Data Scientist – Drug Delivery Device Development
US, Indianapolis IN
Data Science & AI4d ago
$126K - $205K/yr
Scientist - Protein Biochemistry
US, Indianapolis IN
Research & Development4d ago
$80K - $169K/yr
Sr. Director, Medical Affairs - Neuroscience
Canada, Ontario
Medical Affairs4d ago
$170K - $250K/yr
Advisor, Small Molecule Manufacturing Process Quality - Lilly Medicine Foundry
US, Lebanon IN
Manufacturing4d ago
$126K - $205K/yr
Machine Learning Scientist/Sr Scientist, Federated Benchmarking & Validation Engineering
US, Indianapolis IN
Data Science & AI4d ago
$152K - $244K/yr
Sr. Director - GPS Case Management Clinical & Commercial Liaison
US, Indianapolis IN
Clinical Operations4d ago
$156K - $229K/yr
Associate Vice President - Global Facilities Delivery Projects
US, Indianapolis IN
Research & Development4d ago
$201K - $295K/yr
Pharmaceutical Sales – Territory Manager – Neuroscience Specialty
US, Miami FL
Commercial4d ago
$102K - $184K/yr
Sr./Sr. Principal Associate - QC Lab Informatics
US: Lebanon IN LP1
Research & Development4d ago
$65K - $169K/yr
Sr. Computational Statistician
US, Indianapolis IN
Data Science & AI4d ago
$87K - $194K/yr
Medical Development - Next-Generation Incretin
US, Indianapolis IN
Research & Development4d ago
$219K - $356K/yr
Senior Director – Patent Counsel
US, Indianapolis IN
Legal & IP4d ago
$155K - $227K/yr
Scientist/Engineer – Technical Operations - Lilly Medicine Foundry
US, Lebanon IN
Research & Development4d ago
$66K - $172K/yr
Estagiário de Advocacy
Brazil, São Paulo
Research & Development4d ago
Técnica/o Jr de Laboratorio de Control de Calidad
ES: Alcobendas
Research & Development4d ago
Advisor– API/DS Network Contamination & Bioburden Control Strategy
US, Indianapolis IN
Business Development4d ago
$129K - $189K/yr
Advisor - Cleaning Validation – TS/MS
US, Indianapolis IN
Quality4d ago
$129K - $209K/yr
Stage 6/12 mois –Gestion Comptable, Fiscale et Financière F/H
France, Fegersheim
Research & Development4d ago
Operator Formulation/Prep
US, Indianapolis IN
Research & Development4d ago
$36K - $90K/yr
Sr. Manager - Engineering
US, Indianapolis IN
Engineering4d ago
$99K - $145K/yr
Advisor - Pharmacoepidemiologist
US, Indianapolis IN
Research & Development4d ago
$141K - $229K/yr
Associate Director-Tax and Customer Affairs
China, Suzhou Manufacturing-苏州工厂
Research & Development4d ago
Stagiair(e) Medical Affairs – AI & Medical Multichannel
Netherlands, Utrecht
Medical Affairs4d ago
Interview Prep Quick Facts
Portfolio: 159 approved products, 142 clinical trials
Top TAs: Oncology, Metabolic Diseases, Neurology
H-1B (2023): 2 approvals
Publications: 25 in PubMed
SEC Filings: 2 available
Open Roles: 856 active jobs
Portfolio Health
Pre-Launch35 (22%)
Launch1 (1%)
Growth7 (4%)
Peak19 (12%)
LOE Approaching75 (47%)
Post-LOE22 (14%)
159 total products
Therapeutic Area Focus
Oncology
10 marketed782 pipeline
Metabolic Diseases
27 marketed484 pipeline
Neurology
9 marketed248 pipeline
Immunology
4 marketed125 pipeline
Infectious Diseases
3 marketed30 pipeline
Cardiovascular
3 marketed27 pipeline
Nephrology
28 pipeline
Gastroenterology
21 pipeline
Marketed
Pipeline
Financials (FY2025)
Revenue
$34.1B20%
R&D Spend
$9.3B(27%)30%
Net Income
$5.2BCash
$3.3BHiring Trend
Actively Hiring
856
Open Roles
+853
Added
-0
Filled/Removed
Based on last 2 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub